Stenotrophomonas maltophilia – The most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: A prospective multicenter study

Fihman, Vincent; Monnier, Alban Le; Corvec, Stéphane; Jauréguy, Françoise; Tankovic, Jacques; Jacquier, Hervé; Carbonnelle, Étienne; Bille, Emmanuelle; Illiaquer, Marina; Cattoir, Vincent; Zahar, Jean‐Ralph

doi:10.1016/j.jinf.2012.01.001

Cited by 40 publications

(54 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although part of these findings have already been described in previous studies of nosocomial infections caused by A. baumannii and S. maltophilia (11,16), our results extend these findings to other unusual NFGNB pathogens.…”

Section: Resultssupporting

confidence: 88%

See 1 more Smart Citation

Emergence of Unusual Nonfermenting Gram-Negative Nosocomial Pathogens in a Saudi Hospital

2013

View full text Add to dashboard Cite

SUMMARY: This study aimed to determine the frequency of isolation and prevalence of drug resistance in nonfermenting Gram-negative bacilli (NFGNB) other than Pseudomonas aeruginosa and predisposing factors for the acquisition of nosocomial infections caused by these emerging pathogens in a Saudi tertiary care hospital. A total of 125 nonduplicating NFGNB nosocomial strains were isolated, of these, 68 (54.4z) were Acinetobacter baumannii, 26 (20.8z) Stenotrophomonas maltophilia, 14 (11.2z) Alcaligenes faecalis, 12 (9.6z) Chryseobacterium indologenes, and 5 (4z) Ralstonia pickettii. MICs of 11 antibiotics were determined using the reference broth microdilution method. With the exception of colistin that inhibited 100z of A. baumannii isolates, trimethoprim/sulfamethoxazole that inhibited 100z of S. maltophilia isolates, and carbapenems that inhibited 100z of A. faecalis isolates, none of the tested antimicrobial agents inhibited 100z of the other NFGNB spp. Our results emphasize that clinicians and microbiologists should consider A. faecalis, C. indologenes, and R. pickettii as emerging nosocomial pathogens. In addition, local resistance data are essential for helping physicians in deciding an appropriate antibiotic for empirical therapy of infections with these emerging and unusual NFGNB.

show abstract

Section: Resultssupporting

confidence: 88%

“…maltophilia is intrinsically resistant to most b-lactam agents, quinolones, and aminoglycosides; therefore, SXT is the drug of choice for the treatment of S. maltophilia infections (11). In total agreement with these findings, all S. maltophilia isolates in this study were completely susceptible to SXT.…”

Section: Resultssupporting

confidence: 87%

Emergence of Unusual Nonfermenting Gram-Negative Nosocomial Pathogens in a Saudi Hospital

2013

View full text Add to dashboard Cite

show abstract

“…maltophilia is the only species of Stenotrophomonas known to cause human disease (40). S. maltophilia has significant resistance to broad-spectrum antibiotics, resulting in limited treatment options (2,3,6). Currently, the bacteriostatic compound trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred treatment for S. maltophilia infections.…”

Section: Discussionmentioning

confidence: 99%

“…S. maltophilia can cause serious infections, including pneumonia, bloodstream infections, wound/soft-tissue infections, and urinary tract infections (2,4,5). Recently, fatal infections in humans have been documented (6). S. maltophilia is also associated with equine, canine, and feline respiratory infections and bovine mastitis (7)(8)(9).…”

mentioning

confidence: 99%

Characterization of Maltocin P28, a Novel Phage Tail-Like Bacteriocin from Stenotrophomonas maltophilia

Liu

Chen

Zheng

et al. 2013

Appl Environ Microbiol

View full text Add to dashboard Cite

bStenotrophomonas maltophilia is an important global opportunistic pathogen for which limited therapeutics are available because of the emergence of multidrug-resistant strains. A novel bacteriocin, maltocin P28, which is produced by S. maltophilia strain P28, may be the first identified phage tail-like bacteriocin from S. maltophilia. Maltocin P28 resembles a contractile but nonflexible phage tail structure based on electron microscopy, and it is sensitive to trypsin, proteinase K, and heat. SDS-PAGE analysis of maltocin P28 revealed two major protein bands of approximately 43 and 20 kDa. The N-terminal amino acid residues of these two major subunits were sequenced, and the maltocin P28 gene cluster was located on the S. maltophilia P28 chromosome. Our sequence analysis results indicate that this maltocin gene cluster consists of 23 open reading frames (ORFs), and that its gene organization is similar to that of the P2 phage genome and R2 pyocin gene cluster. ORF17 and ORF18 encode the two major structural proteins, which correspond to gpFI (tail sheath) and gpFII (tail tube) of P2 phage, respectively. We found that maltocin P28 had bactericidal activity against 38 of 81 tested S. maltophilia strains. Therefore, maltocin P28 is a promising therapeutic substitute for antibiotics for S. maltophilia infections.

show abstract

“…Only levofloxacin and tigecycline demonstrated in vitro activity against S. maltophilia. The AN3365 results obtained against S. maltophilia are encouraging since the prevalence of this species among hospitalized patients has increased during the last few decades and since infections caused by this MBL-encoding gene-bearing species have led to inappropriate empirical therapy and consequently increased mortality (7,40).…”

mentioning

confidence: 94%

Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli

Mendes

Alley²,

Sader

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

c AN3365 (MIC 50/90 , 0.5/1 g/ml) was active against Enterobacteriaceae, including a subset of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains (MIC 50/90 , 1/2 g/ml). AN3365 inhibited 98.0 and 92.2% of wild-type (MIC 50/90 , 2/8 g/ml) and carbapenem-resistant (MIC 50/90 , 4/8 g/ml) Pseudomonas aeruginosa strains, respectively, at <8 g/ml. AN3365 also demonstrated activity against wild-type Acinetobacter baumannii (MIC 50/90 , 2/8 g/ml) and Stenotrophomonas maltophilia (MIC 50/90 , 2/4 g/ml), while it was less active against multidrug-resistant A. baumannii (MIC 50/90 , 8/16 g/ml) and Burkholderia cepacia (MIC 50/90 , 8/32 g/ml).

show abstract

Stenotrophomonas maltophilia – The most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: A prospective multicenter study

Cited by 40 publications

References 29 publications

Emergence of Unusual Nonfermenting Gram-Negative Nosocomial Pathogens in a Saudi Hospital

Emergence of Unusual Nonfermenting Gram-Negative Nosocomial Pathogens in a Saudi Hospital

Characterization of Maltocin P28, a Novel Phage Tail-Like Bacteriocin from Stenotrophomonas maltophilia

Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli

Contact Info

Product

Resources

About